Chicago-based venture-capital firm Arch Venture Partners has closed a new $3 billion fund to invest in early-stage ...

A biotech-focused venture capital firm in Chicago is ready with a new fund as life sciences and biotech continue to find new ...

On the heels of a $3 billion fund from Bain Capital Life Sciences, Arch Venture Partners is proving it can go toe-to-toe with ...

New revelations from the showdown between Novo Nordisk’s CEO and Bernie Sanders’ Senate health committee Tuesday; PhRMA’s legal victory in IRA case; the federal interest rate cut and anticipated ...

Amid a flurry of weight loss readouts, a fresh-on-the-scene startup has come out with Phase I results showing weight loss at day 36 on par with or better than competitors, with few gastrointestinal ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive topline results from the Phase 1 ...

Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first ...

Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi ...

Led by Metsera and Hercules (both acquisition targets), venture capital/private obesity drug development will layer in new drugs. We sell different types of products and services to both ...